Relay Therapeutics Inc

Relay Therapeutics CFO’s sell‑to‑cover of 972 shares at $14.79 shows routine RSU compliance—no bearish signal, but a key indicator for investors ahead of Q1 2026 earnings.

Relay Therapeutics CFO’s disciplined 10b5‑1 sale signals confidence amid a 52‑week high—investors can gauge future upside by tracking insider trades and earnings.

Relay Therapeutics CFO’s insider sale signals routine liquidity, not distress – a cautious yet confident move amid volatile yet promising oncology prospects.

Patel Sanjiv’s 2025‑26 insider trades show confident, long‑term support for Relay Therapeutics amid promising oncology data, signaling potential value for investors.